PTC wins conditional EU Translarna approval
PTC Therapeutics has been granted conditional approval from the European Commission for its Duchenne muscular dystrophy (DMD) drug Translarna (ataluren), which has yet to produce Phase III data.
PTC Therapeutics has been granted conditional approval from the European Commission for its Duchenne muscular dystrophy (DMD) drug Translarna (ataluren), which has yet to produce Phase III data.